Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
Salvatore PianoCarmine Gabriele GambinoElia VettoreValeria CalvinoMarta TononPatrizia BoccagniEnrico GringeriGiacomo GermaniPatrizia BurraUmberto CilloPaolo AngeliPublished in: Hepatology (Baltimore, Md.) (2021)
In patients with AKI-HRS, response to terlipressin and albumin reduces the need for RRT after LT and reduces the risk of CKD at 1 year after LT.